Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a multi-ingredient bladder instillation (cocktail) used for the treatment of interstitial cystitis and bladder pain syndrome (IC/BPS). It consists of heparin sulphate (a glycosaminoglycan replenisher), lidocaine (a local anesthetic), sodium bicarbonate (an alkalinizing agent), and triamcinolone acetonide (a corticosteroid). The combination is designed to provide immediate pain relief via lidocaine, reduce inflammation via triamcinolone, and restore the protective bladder lining via heparin. It is administered directly into the bladder via a urinary catheter. Corewell Health East (formerly Beaumont Health) evaluated this specific formulation in a Phase 2 clinical trial comparing its efficacy against pelvic floor physical therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + lidocaine + sodium bicarbonate + triamcinolone acetonide.